FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129129812> ?p ?o ?g. }

• W2129129812 endingPage "528" @default.
• W2129129812 startingPage "524" @default.
• W2129129812 abstract "In an RNAi screen targeting chromatin regulators, Vakoc and colleagues find that maintenance of acute myeloid leukaemia (AML) requires Brd4, which binds to acetylated histones to influence gene transcription. Brd4 regulates expression of the oncogene Myc and a Myc-driven gene-expression program that permits leukaemia cells to self-renew. JQ1, a small molecule that inhibits Brd4 function, has anti-leukaemic effects in a mouse model and inhibits the proliferation of primary human AML cells, suggesting a therapeutic approach in patients with AML. Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene expression programs1. Although chromatin alterations are, in principle, reversible and often amenable to drug intervention, the promise of targeting such pathways therapeutically has been limited by an incomplete understanding of cancer-specific dependencies on epigenetic regulators. Here we describe a non-biased approach to probe epigenetic vulnerabilities in acute myeloid leukaemia (AML), an aggressive haematopoietic malignancy that is often associated with aberrant chromatin states2. By screening a custom library of small hairpin RNAs (shRNAs) targeting known chromatin regulators in a genetically defined AML mouse model, we identify the protein bromodomain-containing 4 (Brd4) as being critically required for disease maintenance. Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes. The effects of Brd4 suppression are, at least in part, due to its role in sustaining Myc expression to promote aberrant self-renewal, which implicates JQ1 as a pharmacological means to suppress MYC in cancer. Our results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference (RNAi) screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention." @default.
• W2129129812 created "2016-06-24" @default.
• W2129129812 creator A5000842818 @default.
• W2129129812 creator A5005885108 @default.
• W2129129812 creator A5006306448 @default.
• W2129129812 creator A5007182073 @default.
• W2129129812 creator A5011067274 @default.
• W2129129812 creator A5015010943 @default.
• W2129129812 creator A5016359984 @default.
• W2129129812 creator A5025451142 @default.
• W2129129812 creator A5031538988 @default.
• W2129129812 creator A5032082597 @default.
• W2129129812 creator A5035774267 @default.
• W2129129812 creator A5037115007 @default.
• W2129129812 creator A5043149847 @default.
• W2129129812 creator A5051406099 @default.
• W2129129812 creator A5052025914 @default.
• W2129129812 creator A5072926885 @default.
• W2129129812 creator A5074745892 @default.
• W2129129812 creator A5076751118 @default.
• W2129129812 creator A5083642522 @default.
• W2129129812 creator A5091324982 @default.
• W2129129812 date "2011-08-03" @default.
• W2129129812 modified "2023-10-18" @default.
• W2129129812 title "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia" @default.
• W2129129812 cites W1518437340 @default.
• W2129129812 cites W1901250531 @default.
• W2129129812 cites W1970309962 @default.
• W2129129812 cites W1971311960 @default.
• W2129129812 cites W1973962332 @default.
• W2129129812 cites W1975887213 @default.
• W2129129812 cites W1977729188 @default.
• W2129129812 cites W1977859620 @default.
• W2129129812 cites W1990174038 @default.
• W2129129812 cites W1990320777 @default.
• W2129129812 cites W1992127633 @default.
• W2129129812 cites W2000596495 @default.
• W2129129812 cites W2014624348 @default.
• W2129129812 cites W2015735594 @default.
• W2129129812 cites W2019199359 @default.
• W2129129812 cites W2027127452 @default.
• W2129129812 cites W2041535798 @default.
• W2129129812 cites W2066277278 @default.
• W2129129812 cites W2076426515 @default.
• W2129129812 cites W2094799740 @default.
• W2129129812 cites W2094915354 @default.
• W2129129812 cites W2097743943 @default.
• W2129129812 cites W2101091611 @default.
• W2129129812 cites W2105085478 @default.
• W2129129812 cites W2107398329 @default.
• W2129129812 cites W2109336877 @default.
• W2129129812 cites W2118272259 @default.
• W2129129812 cites W2122659245 @default.
• W2129129812 cites W2123719503 @default.
• W2129129812 cites W2128919238 @default.
• W2129129812 cites W2130410032 @default.
• W2129129812 cites W2131072337 @default.
• W2129129812 cites W2140716778 @default.
• W2129129812 cites W2143358450 @default.
• W2129129812 cites W2144449731 @default.
• W2129129812 cites W2150113701 @default.
• W2129129812 cites W2152333235 @default.
• W2129129812 cites W2154218976 @default.
• W2129129812 cites W2154607830 @default.
• W2129129812 cites W2157305385 @default.
• W2129129812 cites W2164154570 @default.
• W2129129812 doi "https://doi.org/10.1038/nature10334" @default.
• W2129129812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3328300" @default.
• W2129129812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21814200" @default.
• W2129129812 hasPublicationYear "2011" @default.
• W2129129812 type Work @default.
• W2129129812 sameAs 2129129812 @default.
• W2129129812 citedByCount "1615" @default.
• W2129129812 countsByYear W21291298122012 @default.
• W2129129812 countsByYear W21291298122013 @default.
• W2129129812 countsByYear W21291298122014 @default.
• W2129129812 countsByYear W21291298122015 @default.
• W2129129812 countsByYear W21291298122016 @default.
• W2129129812 countsByYear W21291298122017 @default.
• W2129129812 countsByYear W21291298122018 @default.
• W2129129812 countsByYear W21291298122019 @default.
• W2129129812 countsByYear W21291298122020 @default.
• W2129129812 countsByYear W21291298122021 @default.
• W2129129812 countsByYear W21291298122022 @default.
• W2129129812 countsByYear W21291298122023 @default.
• W2129129812 crossrefType "journal-article" @default.
• W2129129812 hasAuthorship W2129129812A5000842818 @default.
• W2129129812 hasAuthorship W2129129812A5005885108 @default.
• W2129129812 hasAuthorship W2129129812A5006306448 @default.
• W2129129812 hasAuthorship W2129129812A5007182073 @default.
• W2129129812 hasAuthorship W2129129812A5011067274 @default.
• W2129129812 hasAuthorship W2129129812A5015010943 @default.
• W2129129812 hasAuthorship W2129129812A5016359984 @default.
• W2129129812 hasAuthorship W2129129812A5025451142 @default.
• W2129129812 hasAuthorship W2129129812A5031538988 @default.
• W2129129812 hasAuthorship W2129129812A5032082597 @default.
• W2129129812 hasAuthorship W2129129812A5035774267 @default.
• W2129129812 hasAuthorship W2129129812A5037115007 @default.

• next